Mesoblast Reports Positive Type 2 Diabetes Trial Results NEW YORK and MELBOURNE, Australia, Dec. 3, 2013 -- Regenerative medicine company Mesoblast Limited today announced top-line results from the Phase 2 trial of its proprietary Mesenchymal Precursor Cells in subjects with type 2 diabetes.
http://www.biospace.com/news_story.aspx?StoryID=317574&full=1
http://www.biospace.com/news_story.aspx?StoryID=317574&full=1
No comments:
Post a Comment